Breaking News

Asahi Kasei Completes Acquisition of Aicuris

Adds three antiviral assets spanning marketed and clinical-stage development, complementing its existing treatment portfolio.

Author Image

By: Charlie Sternberg

Associate Editor

Asahi Kasei has completed its previously announced acquisition of Aicuris Anti-infective Cures AG (Aicuris), a German-based biopharmaceutical company, accelerating its efforts to build a global specialty pharmaceutical platform by expanding further into severe infectious diseases. “The completion of the Aicuris acquisition reflects the deliberate execution of our pharmaceutical strategy and strengthens our position in infectious diseases, a core area where we see sustained demand, high unmet ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters